• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Battle of the Bulge: Obesity and Antipsychotic-Induced Weight Gain

Battle of the Bulge: Obesity and Antipsychotic-Induced Weight Gain

July 14, 2021
Farah Khorassani, PharmD. Clinical Assistant
From The Carlat Hospital Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Farah Khorassani, PharmD. Clinical Assistant Professor of Pharmacy Practice, St. John’s University, Queens, NY. Dr. Khorassani has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Many psychiatric medications cause weight gain, including mood stabilizers, antidepressants, and especially antipsychotics. Most weight gain secondary to antipsychotic use occurs in the first 6 months of therapy, so it’s important to monitor weight closely and intervene early in a patient’s treatment. We counsel patients at every visit about healthy diets, portion control, and regular exercise. This article offers practical pharmacologic strategies for the prevention and treatment of obesity and antipsychotic-induced weight gain (AIWG).

Prevention, switch, and augmentation strategies
The cornerstone of preventing AIWG is antipsychotic selection. Atypical antipsychotics with a low metabolic risk, including aripiprazole, brexpiprazole, cariprazine, lurasidone, and ziprasidone, will minimize weight gain (Musil R et al, Expert Opin Drug Saf 2015;14(1):73–96). Some first-generation agents, like haloperidol, are also less likely to cause metabolic syndrome (Editor’s note: See “Metabolic Side Effects of Antipsychotics” table, below).
Table: Metabolic Side Effects of Antipsychotics

Table: Metabolic Side Effects of Antipsychotics

(Click to view full-sized PDF.)

If patients have gained weight on other antipsychotics, can they lose weight by switching to agents with a low metabolic risk? Probably so, at least for aripiprazole, which is the only agent that’s been studied in this manner. In a 24-week study of 206 overweight patients who were randomized to continue on olanzapine, quetiapine, or risperidone or to switch to aripiprazole, patients who switched to aripiprazole experienced significantly greater weight reduction (3.7 kg) compared to patients who continued on their previous medications (0.7 kg) (Stroup TS et al, Am J Psychiatry 2011;168(9):947–956). The study included a diet and exercise program for all subjects.

If changing from an antipsychotic with high metabolic risk is not feasible, augmenting the antipsychotic with low or medium doses of aripiprazole (5–15 mg/day) can help. This strategy stood out as the most effective pharmacologic intervention in a recent comprehensive meta-analysis (Vancampfort D et al, World Psychiatry 2019;18(1):53–66).

Pharmacologic treatment of AIWG

Metformin
Metformin (Glucophage) (500–1000 mg twice daily) is the best-studied and most widely used medication to treat AIWG. It produces a weight loss, on average, of about 3 kg (de Silva VA et al, BMC Psychiatry 2016;16(1):341) or about a 3% reduction in body weight, compared to a 1% reduction with placebo (Jarskog LF et al, Am J Psychiatry 2013;170(9):1032–1040). While this is not as much weight loss as seen with other agents, metformin is well tolerated and safe, and it helps treat insulin resistance—an additional benefit, given that many of our patients are diabetic or prediabetic. Nausea and diarrhea occur in 25%–50% of patients early in treatment; these side effects are minimized by taking metformin with food or using the extended-release formulation. Patients must be screened for liver or kidney impairment as both increase the risk of lactic acidosis in patients on this medication. If a patient’s eGFR is less than 60 mL/minute, adjust the dosing.
Table: Metformin Dosing: Renal Impairment

Table: Metformin Dosing: Renal Impairment

(Click to view full-sized PDF.)

Should we start metformin prophylactically to prevent AIWG? This question has not been well studied, but research generally supports this practice. For example, a 12-week study of patients randomized to olanzapine 15 mg plus metformin 750 mg (n = 20), vs olanzapine 15 mg plus placebo (n = 20), found that the 63% of patients taking olanzapine + placebo increased their weight by more than 7% vs only 17% of patients taking olanzapine + metformin (Wu RR et al, Am J Psychiatry 2008;165(3):352–358). A randomized controlled trial is currently underway evaluating prophylactic metformin for patients starting clozapine (Siskind D et al, BMJ Open 2018;8(3):e021000).

Topiramate (Topamax)
Topiramate (50–400 mg per day) produces more weight loss than metformin, averaging about 4 kg (Goh KK et al, Int J Psychiatry Clin Pract 2019;23(1):14–32). However, about 30% of patients—especially those at higher doses—experience cognitive impairments, including problems with memory and attention (a reason it is jokingly referred to as “Dopamax”). Monitor vision because of the increased risk of angle-closure glaucoma. Additionally, use caution when prescribing topiramate to pregnant women (increased risk of cleft palate) and to women on birth control pills (topiramate induces the metabolism of estrogen and can diminish the efficacy of the contraceptive).

Olanzapine/samidorphan
We will soon have a new treatment option to mitigate olanzapine-induced weight gain: a combination of olanzapine with samidorphan, an opioid receptor antagonist. In a recent study that compared weight changes in patients receiving this combination to patients receiving olanzapine alone, weight increased 4.2% in the olanzapine/samidorphan group compared to 6.6% in the olanzapine monotherapy group (Correll CU et al, Am J Psychiatry 2020;177(12):1168–1178). The FDA approved this combined olanzapine-samidorphan formulation (Lybalvi) on June 1, 2021 (Editor’s note: See the Research Update that covers AIWG for more information).

Other weight loss medications to consider
Numerous medications are on the market for weight loss (Editor’s note: See “FDA-Approved Medications to Treat Obesity” table below). The list used to be longer, but two medications—sibutramine (Meridia) and lorcaserin (Belviq)—were recently withdrawn due to elevated risks of cardiovascular events and cancer, respectively. Selection is determined by side effect profiles, cost, insurance coverage, method of administration (oral vs subcutaneous), and estimated length of treatment, as some medications have only been approved for short-term use. With the exception of liraglutide, these medications have been studied for obesity, but not for obesity secondary to antipsychotic drug use.

Orlistat (Xenical)
Orlistat inhibits the action of lipase in the gastrointestinal tract, thereby preventing the breakdown and absorption of fats through the small intestine. Compared to other medications for obesity, orlistat produces the least weight loss (2.6 kg) (Khera R et al, JAMA 2016;315(22):2424–2434). Further, orlistat’s primary side effects are diarrhea and fatty stools over the first 4 weeks. It’s dosed at 120 mg TID with meals, and patients should take vitamin supplements to ensure they get their daily A, D, E, and K. Orlistat has the advantage of being available over the counter in a lower-dose called Alli.

Liraglutide (Victoza, Saxenda)
Liraglutide is a glucagon-like peptide-1 agonist (GLP-1 agonist) that lowers blood sugar and weight by decreasing both glucose production and appetite and by increasing insulin sensitivity. Of all the weight loss agents, it produces the greatest average weight loss (5.2 kg) compared to placebo (Khera et al, 2016). Liraglutide is FDA approved for type II diabetes as well as for obesity and appears effective for AIWG: A study of patients (n = 97) taking clozapine or olanzapine who were randomized to add-on treatment with either liraglutide (1.2–1.8 mg daily) or placebo found that those in the liraglutide group lost an average of 4.7 kg compared to a gain of 0.5 kg in the placebo group (Larsen JR et al, JAMA Psychiatry 2017;74(7):719–728). There are some serious trade-offs, though: Liraglutide is administered subcutaneously, and it causes nausea in about two-thirds of patients.

Semaglutide (Ozempic, Wegovy)
Semaglutide is another GLP-1 agonist that has been in the news lately due to its reported efficacy as a weight loss agent. A recent study randomized non-diabetic patients with a BMI of 30 or more (n = 1961) to once-weekly subcutaneous semaglutide 2.4 mg or placebo, plus lifestyle intervention (Wilding JPH et al, N Engl J Med 2021;384(11):989). After 68 weeks, patients in the semaglutide group lost an average of 15% of their baseline body weight, or 33.7 pounds, compared to 2.4%, or 5.7 pounds, in the placebo group. The weight loss began early in treatment: Patients on semaglutide experienced more than a 2% reduction in body weight within the first 4 weeks. Side effects consisted primarily of transient nausea and diarrhea. In June 2021, the FDA approved semaglutide for weight loss (in addition to its indication for type 2 diabetes).

Sympathomimetics
Medications like phentermine (Adipex-P, Lomaira) are effective in inducing weight loss but have only been approved for short-term obesity management (ie, a few months). Watch for new onset of psychosis when patients take these agents. They are not good choices for patients with substance use disorders because of their abuse potential, or for patients with primary psychotic ­disorders.

Co-formulated agents
Phentermine/topiramate (Qsymia) and bupropion/naltrexone (Contrave) are substantially more effective than these medications taken alone, so they are marketed as combination tablets. Qsymia produces 8%–10% reduction in weight vs about 1% with placebo (Gadde KM et al, Lancet 2011;377(9774):1341–1352). Similarly, Contrave leads to 5%–6% reduction in weight vs 1% with placebo (Greenway FL et al, Lancet 2010;376(9741):595–605).

While these findings appear promising, we need to be cautious when prescribing Qsymia or Contrave in certain populations. Avoid bupropion in patients with eating or seizure disorders, avoid naltrexone in opioid users and patients with liver dysfunction, and use caution when prescribing topiramate to pregnant women or women on birth control pills.

CHPR Verdict: There are several options for treating AIWG—though none are likely to yield spectacular weight loss. Metformin (Glucophage) and topiramate (Topamax) are commonly used and relatively safe. Liraglutide also helps, but many patients don’t want to use injectable medications. A new kid on the block, olanzapine/samidorphan, looks promising if it gains FDA approval. In addition, there are many other meds designed for general weight loss that have not been studied for AIWG but may be worth trying in select patients.
Table: FDA-Approved Medications to Treat Obesity

Table: FDA-Approved Medications to Treat Obesity

(Click to view full-sized PDF.)
Hospital Psychiatry
KEYWORDS aripiprazole benzphetamine bupropion diabetes diethylpropion exercise insulin-resistance liraglutide metabolic-syndrome metformin naltrexone olanzapine phendimetrazine phentermine samidorphan semaglutide side-effects topiramate waist-circumference weight-gain ziprasidone
    Farah Khorassani, PharmD. Clinical Assistant

    More from this author
    www.thecarlatreport.com
    Issue Date: July 14, 2021
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Metabolic Side Effects, CHPR, July/August/September 2021
    Battle of the Bulge: Obesity and Antipsychotic-Induced Weight Gain
    Weight Gain and Metabolic Side Effects
    Sex-Based Treatment of Schizophrenia
    New Combination Treatment Mitigates Antipsychotic-Induced Weight Gain
    Anti-NMDA Receptor Encephalitis or New-Onset Psychosis?
    Psilocybin: The New Holy Grai­l for the Rapid Relief of Major ­Depression?
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.